234 related articles for article (PubMed ID: 18093454)
21. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
22. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
Hashimoto H; Iwasa S; Yanai T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Namikawa K; Tsutsumida A; Yamazaki N; Yamamoto H
Jpn J Clin Oncol; 2013 Jan; 43(1):92-4. PubMed ID: 23136238
[TBL] [Abstract][Full Text] [Related]
24. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
25. A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser.
Choi JW; Kim TI; Jeong KH; Shin MK
Dermatol Ther; 2016 Jul; 29(4):252-4. PubMed ID: 27146102
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy.
Micantonio T; Fargnoli MC; Ricevuto E; Ficorella C; Marchetti P; Peris K
Arch Dermatol; 2005 Sep; 141(9):1173-4. PubMed ID: 16172328
[No Abstract] [Full Text] [Related]
27. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
28. [Acneiform eruption secondary to cetuximab].
Herrera-Acosta E; Martín-Ezquerra G; Iglesias M; Umbert P
Actas Dermosifiliogr; 2005 May; 96(4):252-4. PubMed ID: 16476378
[TBL] [Abstract][Full Text] [Related]
29. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
[TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz HJ
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
33. Neutrophilic eccrine hidradenitis induced by cetuximab.
Turan H; Kaya E; Gurlevik Z; Erdem H; Oktay M
Cutan Ocul Toxicol; 2012 Jun; 31(2):148-50. PubMed ID: 22034841
[TBL] [Abstract][Full Text] [Related]
34. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
35. [Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes].
Vidal-Olmo I; Bassas-Vila J; Herrera-Acosta E; Umbert-Millet P
Actas Dermosifiliogr; 2008 Mar; 99(2):159-60. PubMed ID: 18346444
[No Abstract] [Full Text] [Related]
36. Cetuximab-induced acne.
Molinari E; De Quatrebarbes J; André T; Aractingi S
Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
[TBL] [Abstract][Full Text] [Related]
37. Papulo-pustular eruption during cetuximab treatment.
Satta R; Cuccuru MA; Pirodda C; Cottoni F
G Ital Dermatol Venereol; 2008 Feb; 143(1):87-8. PubMed ID: 18833056
[No Abstract] [Full Text] [Related]
38. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Chong G; Cunningham D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
[TBL] [Abstract][Full Text] [Related]
39. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
